GENFIT Share Price Xetra
Stocks
XUP
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Xetra
12:36:45 10/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 14.08 EUR | -1.81% |
|
-1.81% | +164.41% |
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 65Cr 75Cr 61Cr 56Cr 104.56Cr 7.19TCr 106.35Cr 717.5Cr 280.42Cr 3.61TCr 282.72Cr 276.84Cr 12TCr | P/E 2026 * |
33.6x | P/E 2027 * | 86.5x |
|---|---|---|---|---|---|
| Enterprise Value | 60Cr 69Cr 56Cr 51Cr 96Cr 6.62TCr 98Cr 661.19Cr 258.41Cr 3.33TCr 260.53Cr 255.11Cr 11TCr | EV / Sales 2026 * |
5.99x | EV / Sales 2027 * | 4.72x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -1.81% | ||
| 1 week | -1.81% | ||
| Current month | +2.77% | ||
| 1 month | +5.39% | ||
| 3 months | +53.38% | ||
| 6 months | +167.68% | ||
| Current year | +164.41% |
| 1 week | 14.08 |  | 14.08 |
| 1 month | 13.7 | | 14.34 |
| Current year | 5.2 | | 14.34 |
| 1 year | 3.19 | | 14.34 |
| 3 years | 3.19 | | 14.34 |
| 5 years | 3.19 | | 14.34 |
| 10 years | 3.19 | | 14.34 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.81% | -1.81% | - | - | 75Cr | |
| -1.78% | -1.68% | +1.48% | +15.31% | 4.84TCr | |
| +0.85% | -0.70% | +460.88% | +563.55% | 4.37TCr | |
| -2.40% | -0.23% | +8.13% | +71.41% | 3.95TCr | |
| -2.01% | -0.85% | +23.85% | +8.73% | 3.9TCr | |
| -0.50% | +0.85% | +20.60% | +49.65% | 3.26TCr | |
| +0.38% | -3.23% | - | - | 1.63TCr | |
| -0.59% | -2.06% | +26.35% | +118.09% | 1.61TCr | |
| +0.49% | +0.92% | +4.11% | +26.37% | 1.42TCr | |
| -0.43% | +4.70% | +78.74% | +33.31% | 1.34TCr | |
| Average | -0.78% | +0.49% | +78.02% | +110.80% | 2.92TCr | |
| Weighted average by Cap. | -0.92% | +0.59% | +95.83% | +133.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10Cr 12Cr 9.43Cr 8.56Cr 16Cr 1.11TCr 16Cr 110.38Cr 43Cr 555.4Cr 43Cr 43Cr 1.85TCr | 12Cr 14Cr 12Cr 11Cr 20Cr 1.37TCr 20Cr 136.65Cr 53Cr 687.6Cr 54Cr 53Cr 2.29TCr |
| Net income | 2.29Cr 2.65Cr 2.15Cr 1.96Cr 3.67Cr 252.49Cr 3.74Cr 25Cr 9.85Cr 126.82Cr 9.93Cr 9.72Cr 421.6Cr | 68L 78.71L 63.97L 58.11L 1.09Cr 75Cr 1.11Cr 7.49Cr 2.93Cr 38Cr 2.95Cr 2.89Cr 125.31Cr |
| Net Debt | -5.11Cr -5.92Cr -4.81Cr -4.37Cr -8.21Cr -564.16Cr -8.35Cr -56Cr -22Cr -283.35Cr -22Cr -22Cr -942.01Cr | -6.62Cr -7.66Cr -6.22Cr -5.65Cr -11Cr -730.32Cr -11Cr -73Cr -28Cr -366.8Cr -29Cr -28Cr -1.22TCr |
| Date | Price | Change | Volume |
|---|
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
Select your edition
All financial news and data tailored to specific country editions
